Addressing Inequities in Cancer Drug Benefits for Minority Patients
The WPA expresses deep concern over a recent study published in JAMA Oncology in January 2025, which highlights significant disparities in the effectiveness and accessibility of targeted cancer drugs among patients of different racial and ethnic backgrounds. The study underscores that these cutting-edge therapies, while groundbreaking, disproportionately benefit White patients due to systemic issues in clinical trials and genetic datasets.
Key Findings:
• Targeted cancer drugs have predominantly benefited White patients, with significantly lower eligibility and efficacy rates observed in Black, Asian, and other minority populations.
• Clinical trials and genetic datasets have historically included mostly White patients, resulting in a lack of diversity in biomarker discovery and drug development.
• Between 2012 and 2023, the likelihood of matching with FDA-approved targeted therapies increased disproportionately:
o 9.1-fold for patients of European ancestry.
o Only 6-fold for patients of African ancestry, the lowest among all groups studied.
Andrew Spiegel, WPA Chair, stated that “these findings underscore a critical gap in the inclusivity of cancer drug development and emphasize the urgent need for systemic changes to achieve equitable healthcare for all”. The WPA emphasizes:
1. Diversity in Clinical Trials: Urgent action is required to recruit and include more patients from underrepresented racial and ethnic groups in clinical trials to ensure drugs are effective across diverse populations.
2. Equity in Drug Development: Genetic datasets used for biomarker discovery must be representative of global populations, not just those of European descent.
3. Addressing Disparities: Tailored strategies should be implemented to address the unique needs of minority groups, ensuring equal access to life-saving treatments.
Andrew Spiegel urged the regulators, pharmaceutical companies, and healthcare policymakers to:
• Mandate diversity in clinical trial design and execution.
• Invest in building genetic datasets that reflect global diversity.
• Provide transparent reporting on the inclusivity and real-world impact of approved drugs.
• Collaborate with patient advocacy organizations to ensure all voices are heard in drug development and distribution processes.
While targeted cancer therapies represent a beacon of hope, they must not deepen healthcare inequities. WPA is committed to advocating for patient-centered policies and practices that prioritize equity, ensuring that innovations benefit all populations equally.
